Valuation : Inotiv, Inc.

Market Cap 4L 3L 3L 3L 5L 3.66Cr 5L 36.99L 14.4L 1.87Cr 14.54L 14.23L 6.03Cr P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 44Cr 38Cr 35Cr 32Cr 60Cr 4.14TCr 61Cr 418.29Cr 162.9Cr 2.12TCr 164.45Cr 160.87Cr 6.81TCr EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.37%
Yield 2024 *
-
Yield 2025 -
1 day-26.00%
3 months-90.73%
6 months-96.10%
Current year-98.03%
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
1.68
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 12/01/2019
Director of Finance/CFO 61 06/03/2020
Chief Operating Officer 60 15/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
19/07/26 Others

Chief Executive Officer

-13,61,215 3.9017%
19/07/26 Others

Director

-7,29,626 2.0913%
19/07/26 Others

Chief Financial Officer

-1,39,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%-.--%-99.30%-99.71% 4L
-2.23%-2.50%-1.56%+14.92% 5.03TCr
-0.77%+0.74%+437.66%+521.60% 4.52TCr
-2.57%+0.92%+43.50%+19.59% 4.47TCr
-0.87%-1.64%+13.17%+76.09% 4.12TCr
+0.43%-2.20%+14.55%+49.08% 3.31TCr
-1.84%+7.45% - - 1.78TCr
-0.59%-2.58%+21.31%+120.72% 1.66TCr
-0.76%+0.75%+16.12%+28.30% 1.48TCr
-1.94%-1.25%+77.36%+40.91% 1.4TCr
Average -3.73%-3.97%+58.09%+85.72% 2.78TCr
Weighted average by Cap. -1.33%-0.64%+93.66%+126.77%

Financials

2024 2025
Net sales 49Cr 42Cr 40Cr 36Cr 68Cr 4.64TCr 68Cr 468.73Cr 182.54Cr 2.37TCr 184.28Cr 180.26Cr 7.64TCr 51Cr 44Cr 41Cr 38Cr 71Cr 4.85TCr 71Cr 490.01Cr 190.83Cr 2.48TCr 192.65Cr 188.45Cr 7.98TCr
Net income -11Cr -9.33Cr -8.76Cr -8.01Cr -15Cr -1.03TCr -15Cr -103.58Cr -40Cr -523.88Cr -41Cr -40Cr -1.69TCr -6.86Cr -5.9Cr -5.54Cr -5.07Cr -9.46Cr -648.72Cr -9.54Cr -66Cr -26Cr -331.52Cr -26Cr -25Cr -1.07TCr
Net Debt 42Cr 36Cr 34Cr 31Cr 58Cr 4.01TCr 59Cr 404.69Cr 157.6Cr 2.05TCr 159.1Cr 155.63Cr 6.59TCr 44Cr 38Cr 35Cr 32Cr 60Cr 4.14TCr 61Cr 417.92Cr 162.75Cr 2.11TCr 164.31Cr 160.72Cr 6.81TCr
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTV Stock